| Primary |
| Drug Use For Unknown Indication |
28.0% |
| Thrombosis Prophylaxis |
20.4% |
| Product Used For Unknown Indication |
10.3% |
| Deep Vein Thrombosis |
8.9% |
| Pulmonary Embolism |
5.3% |
| Hypertension |
3.9% |
| Pain |
3.0% |
| Prophylaxis |
2.8% |
| Phlebitis |
2.7% |
| Atrial Fibrillation |
2.4% |
| Infection Prophylaxis |
2.2% |
| Thrombophlebitis |
1.5% |
| Thrombosis |
1.5% |
| Acute Coronary Syndrome |
1.3% |
| Analgesia |
1.1% |
| Insomnia |
1.0% |
| Constipation |
1.0% |
| Erysipelas |
1.0% |
| Gastritis |
0.8% |
| Depression |
0.8% |
|
| Pulmonary Embolism |
10.7% |
| Haemorrhage |
8.9% |
| Death |
8.3% |
| Haematoma |
6.6% |
| Vomiting |
6.6% |
| Thrombosis |
6.3% |
| Thrombocytopenia |
6.1% |
| Off Label Use |
5.7% |
| Subdural Haematoma |
4.7% |
| Post Procedural Haemorrhage |
4.4% |
| Shock Haemorrhagic |
4.1% |
| Muscle Haemorrhage |
3.9% |
| Melaena |
3.7% |
| Pain In Extremity |
3.3% |
| Product Quality Issue |
3.2% |
| Drug Ineffective |
2.8% |
| Deep Vein Thrombosis |
2.7% |
| Incorrect Drug Administration Duration |
2.7% |
| Pyrexia |
2.7% |
| Overdose |
2.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
38.2% |
| Product Used For Unknown Indication |
20.5% |
| Deep Vein Thrombosis |
6.1% |
| Thrombosis Prophylaxis |
5.4% |
| Pulmonary Embolism |
4.2% |
| Atrial Fibrillation |
2.9% |
| Prophylaxis |
2.7% |
| Pain |
2.2% |
| Hypertension |
1.9% |
| Adenocarcinoma |
1.8% |
| Cardiac Failure |
1.7% |
| Acute Coronary Syndrome |
1.6% |
| Lung Infection |
1.6% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Depression |
1.4% |
| Metastases To Lymph Nodes |
1.3% |
| Sepsis |
1.3% |
| Trousseau's Syndrome |
1.3% |
| Breast Cancer |
1.2% |
| Bronchitis |
1.2% |
|
| Thrombocytopenia |
19.8% |
| Urine Colour Abnormal |
8.4% |
| Muscle Haemorrhage |
6.9% |
| Subdural Haematoma |
5.3% |
| Haemoptysis |
4.6% |
| Neutropenia |
4.6% |
| Pyrexia |
4.6% |
| Renal Failure Acute |
4.6% |
| Vomiting |
4.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.8% |
| Haematoma |
3.8% |
| Oedema Peripheral |
3.8% |
| Rhabdomyolysis |
3.8% |
| Angioedema |
3.1% |
| Coma |
3.1% |
| Gastrointestinal Haemorrhage |
3.1% |
| Intra-abdominal Haematoma |
3.1% |
| Platelet Count Decreased |
3.1% |
| Pulmonary Arterial Hypertension |
3.1% |
| Pulmonary Embolism |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.6% |
| Drug Use For Unknown Indication |
19.7% |
| Hypertension |
6.4% |
| Prophylaxis |
5.7% |
| Pain |
5.4% |
| Multiple Myeloma |
4.3% |
| Anticoagulant Therapy |
3.9% |
| Thrombosis Prophylaxis |
3.7% |
| Non-small Cell Lung Cancer |
3.3% |
| Diarrhoea |
2.7% |
| Paroxysmal Nocturnal Haemoglobinuria |
2.5% |
| Rheumatoid Arthritis |
2.5% |
| Thrombosis |
2.4% |
| Breast Cancer |
2.3% |
| Pulmonary Embolism |
1.9% |
| Colorectal Cancer Metastatic |
1.4% |
| Nausea |
1.4% |
| Anxiety |
1.4% |
| Premedication |
1.3% |
| Deep Vein Thrombosis |
1.3% |
|
| Pulmonary Embolism |
17.6% |
| Weight Decreased |
11.0% |
| Thrombocytopenia |
10.7% |
| Vomiting |
8.1% |
| Death |
4.9% |
| Platelet Count Decreased |
4.3% |
| Urinary Tract Infection |
4.3% |
| Pyrexia |
4.0% |
| Septic Shock |
3.8% |
| Thrombosis |
3.8% |
| Venous Thrombosis Limb |
3.5% |
| Anaemia |
3.2% |
| Rash |
2.9% |
| Respiratory Failure |
2.9% |
| Nausea |
2.6% |
| Pleural Effusion |
2.6% |
| Renal Failure Acute |
2.6% |
| Tachycardia |
2.6% |
| Hepatic Encephalopathy |
2.3% |
| Sensory Loss |
2.3% |
|
| Interacting |
| Acute Myocardial Infarction |
26.2% |
| Pulmonary Embolism |
7.1% |
| Acute Coronary Syndrome |
4.8% |
| Arrhythmia |
4.8% |
| Drug Use For Unknown Indication |
4.8% |
| Essential Hypertension |
4.8% |
| Hypertension |
4.8% |
| Hypotension |
4.8% |
| Osteoarthritis |
4.8% |
| Peripheral Arterial Occlusive Disease |
4.8% |
| Product Used For Unknown Indication |
4.8% |
| Sedation |
4.8% |
| Anxiety Disorder |
2.4% |
| Arthritis |
2.4% |
| Atrial Fibrillation |
2.4% |
| Back Pain |
2.4% |
| Cardiac Disorder |
2.4% |
| Diabetes Mellitus |
2.4% |
| Hypercholesterolaemia |
2.4% |
| Oedema Peripheral |
2.4% |
|
| Upper Gastrointestinal Haemorrhage |
22.2% |
| Coagulopathy |
11.1% |
| Product Quality Issue |
11.1% |
| Rectal Haemorrhage |
11.1% |
| Renal Failure Acute |
11.1% |
| Renal Failure Chronic |
11.1% |
| Shock |
11.1% |
| Shock Haemorrhagic |
11.1% |
|
